Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Definium Therapeutics Inc. Common Shares trades at $36.68 (market cap $4.59B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.62 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 5.5× Definium Therapeutics Inc. Common Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| DFTX | RPRX | |
|---|---|---|
Market Cap | $4.59B | $25.27B |
Volume | 2,103,937 | 3,671,183 |
Sector | Health | Health |
52-Week High | $48.45 | $63.96 |
52-Week Low | $10.68 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.55B | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
